Logo for Surface Oncology Inc

Surface Oncology Investor Relations Material

Latest events

Logo for Surface Oncology

Q2 2023

2 Aug, 2023
Logo for Surface Oncology

Q1 2023

4 May, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Surface Oncology Inc

Access all reports
Surface Oncology Inc is a clinical-stage immuno-oncology company dedicated to the development of novel antibody therapies for the treatment of cancer. Its focus lies in creating and advancing treatments designed to modify the tumor microenvironment, thereby supporting and sustaining anti-tumor immune responses. The company's product portfolio includes SRF388, aimed at treating diseases such as renal cell carcinoma, hepatocellular carcinoma, and non-small cell lung cancer, as well as SRF617 for various tumors including gastric cancer, prostate cancer, PD-(L)1 relapsed cancer, and pancreatic cancer. Surface Oncology is also working on SRF114, NZV930, and GSK4381562 antibodies, alongside conducting research and development activities and pre-clinical studies. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.